Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is AbbVie Stock a Buy Now?

TheMotleyFool

0 0

Drugmaker AbbVie (NYSE: ABBV) has historically been a safe, market-beating stock to own. Over the past five years, its total returns (which include dividend income) of 191% have eclipsed the S&P 500, which has increased by 113% when factoring in its distributions.

But there have been question marks about the future of AbbVie, especially with the company losing patent protection for its top-selling drug, Humira, next year. However, it has made moves, such as the acquisition of Botox-maker Allergan in 2020, to help diversify and grow its business. Should investors be worried about the stock, or is AbbVie likely to continue outperforming the market?

Image source: Getty Images.

Source Fool.com

Like: 0

ABBV

Share